#1 Clinical Trials Search in Europe

Efinopegdutide

Efinopegdutide, also known as MK-6024, HM12525A, or JNJ-64565111, is a promising drug currently being studied in clinical trials for its potential in treating various liver conditions, particularly nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). These trials aim to evaluate the drug’s safety, efficacy, and how well patients tolerate it. The studies focus on efinopegdutide’s ability to reduce liver fat content, improve liver function, and its effects on body weight and other metabolic parameters.

Table of Contents

What is Efinopegdutide?

Efinopegdutide, also known as MK-6024, HM12525A, or JNJ-64565111, is a new drug currently being studied for its potential to treat various liver and metabolic disorders[1][2][3][4][5]. It is being developed as a promising treatment option for patients suffering from conditions related to fatty liver disease and metabolic dysfunction.

What Conditions Does Efinopegdutide Treat?

Efinopegdutide is being studied for the treatment of several conditions, including:

  • Non-alcoholic Fatty Liver Disease (NAFLD): A condition where excess fat accumulates in the liver of people who drink little or no alcohol[4][5].
  • Non-alcoholic Steatohepatitis (NASH): A more severe form of NAFLD, where the liver becomes inflamed and damaged due to fat accumulation[4][5].
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A newer term used to describe fatty liver disease associated with metabolic dysfunction[2].
  • Hepatic Impairment: Reduced liver function, which can be a result of various liver diseases[1].

How Does Efinopegdutide Work?

While the exact mechanism of action is not fully described in the provided clinical trial information, efinopegdutide is being studied for its effects on liver fat content and metabolic parameters. It is administered as a subcutaneous injection and appears to have effects on reducing liver fat, body weight, and improving various metabolic markers[4][5].

How is Efinopegdutide Administered?

Efinopegdutide is administered as a subcutaneous injection, which means it is injected just under the skin. The dosing regimens being studied vary, but generally involve a dose-escalation approach, where the dose is gradually increased over time. For example:

  • Starting with lower doses (e.g., 2 mg) and increasing to higher doses (e.g., 4 mg, 7 mg, or 10 mg) over several weeks[2][4].
  • Some studies are exploring weekly injections, while others are looking at injections every two weeks[2].

Current Clinical Trials

Efinopegdutide is currently being studied in several clinical trials:

  • Phase 2b trials for precirrhotic NASH, comparing its efficacy to placebo and other treatments like semaglutide[4][5].
  • Studies evaluating its effects on liver fat content, body weight, and various metabolic markers[4][5].
  • Trials assessing its safety and how it’s processed by the body (pharmacokinetics) in people with liver impairment[1].
  • Studies in healthy obese individuals to understand its effects and optimal dosing[3].

Potential Side Effects

As with any medication, efinopegdutide may cause side effects. The clinical trials are closely monitoring for adverse events (AEs), which are any undesirable experiences associated with the use of the drug. Some key points about side effects:

  • The trials are tracking the number of participants who experience adverse events[3][4][5].
  • They’re also monitoring how many participants discontinue the treatment due to side effects[3][4][5].
  • Specific side effects are not detailed in the provided information, as the trials are still ongoing and collecting this data.

Future Prospects

Efinopegdutide shows promise in the treatment of liver and metabolic disorders. The ongoing clinical trials aim to:

  • Determine its effectiveness in reducing liver fat content[4][5].
  • Assess its impact on body weight and metabolic markers like cholesterol and triglycerides[5].
  • Evaluate its safety profile and optimal dosing regimens[1][2][3].
  • Compare its effectiveness to existing treatments like semaglutide[5].

If successful, efinopegdutide could potentially offer a new treatment option for patients with NAFLD, NASH, and related metabolic disorders. However, it’s important to note that as the drug is still in clinical trials, more research is needed to fully understand its benefits and risks.

Aspect Details
Drug Name Efinopegdutide (also known as MK-6024, HM12525A, JNJ-64565111)
Administration Subcutaneous injection, typically in dose-escalation regimens
Main Conditions Studied Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Obesity
Primary Outcomes Reduction in liver fat content, NASH resolution, safety and tolerability
Secondary Outcomes Changes in body weight, cholesterol levels, liver fibrosis
Trial Durations Typically 24 to 52 weeks
Comparators Placebo, Semaglutide
Key Measurements MRI-PDFF for liver fat, liver biopsy for NASH, blood tests for metabolic parameters

FAQ

  • What is efinopegdutide and what conditions is it being studied for? Efinopegdutide is an investigational drug being studied for the treatment of liver conditions such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It's also being evaluated for its effects on body weight in obese individuals.
  • How is efinopegdutide administered in clinical trials? In the clinical trials, efinopegdutide is typically administered as a subcutaneous (under the skin) injection. The dosing regimens vary, but often involve a dose-escalation approach, starting with lower doses and gradually increasing to higher doses over several weeks.
  • What are the main goals of the efinopegdutide clinical trials? The main goals of these trials include evaluating the drug's safety and tolerability, its effectiveness in reducing liver fat content, its impact on body weight, and its effects on various metabolic parameters such as cholesterol levels.
  • How long do the efinopegdutide clinical trials typically last? The duration of the trials varies, but many of them last between 24 to 52 weeks. Some studies also include follow-up periods to assess long-term effects and safety.
  • How does efinopegdutide compare to other treatments in the trials? Some trials compare efinopegdutide to placebo (a substance with no active drug), while others compare it to active treatments like semaglutide. These comparisons help researchers understand how effective efinopegdutide is relative to existing treatments or no treatment at all.

Ongoing Clinical Trials on Efinopegdutide

  • Study on Efinopegdutide for Adults with Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis

    Not recruiting

    2 1
    Investigated drugs:
    France Spain

  • Study on Efinopegdutide and Semaglutide for Adults with Non-Alcoholic Steatohepatitis (NASH) Before Cirrhosis

    Not recruiting

    2 1 1
    Investigated drugs:
    Austria Belgium Czechia France Hungary Italy +2

Glossary

  • Nonalcoholic Fatty Liver Disease (NAFLD): A condition where excess fat builds up in the liver of people who drink little or no alcohol. It's the most common form of chronic liver disease in developed countries.
  • Nonalcoholic Steatohepatitis (NASH): A more severe form of NAFLD, where in addition to fat accumulation, there is inflammation and liver cell damage, which can lead to fibrosis, cirrhosis, and liver failure.
  • Liver Fat Content (LFC): The amount of fat stored in the liver, often measured as a percentage. Reducing LFC is a key goal in treating NAFLD and NASH.
  • Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF): A non-invasive imaging technique used to accurately measure the amount of fat in the liver.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Dose Escalation: A strategy in clinical trials where the dose of a drug is gradually increased over time to find the optimal balance between effectiveness and side effects.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Blinded Independent Central Review (BICR): A process where medical images or data are reviewed by expert readers who are unaware of the treatment assignments, ensuring unbiased assessment.
  • Fibrosis: The formation of excess fibrous connective tissue in an organ or tissue, often as a result of injury or chronic inflammation.

References

  1. https://clinicaltrials.gov/study/NCT06052566
  2. https://clinicaltrials.gov/study/NCT06482112
  3. https://clinicaltrials.gov/study/NCT06701305
  4. https://clinicaltrials.gov/study/NCT05877547
  5. https://clinicaltrials.gov/study/NCT04944992